VEGFA and neoplasm: Sunitinib (Sutent®) and sorafenib (Nexavar®) are tyrosine kinase inhibitors that interrupt tumor proliferation and angiogenesis by inhibiting vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors [12,13].